VPN Plus+ ExclusiveWhat to look for in a quality CBD productNovember 3, 2022Imagine if the pharmaceuticals we prescribe for animals harbored unclear and undisclosed ingredients, in any quantity, with minimal evidence about their safety or effectiveness, and chemical makeup that varied with each shipment. This might sound intolerable, but it describes the status of not only cannabis, but botanical medicine in general.
SPONSORED CONTENTAre Your Patients Fully Protected?Fleas, ticks, heartworms, and intestinal parasites—dogs face multiple threats. See how a multi-parasite approach can offer your patients a broad range of protection. + Learn More
Ambiguity, shorthand can lead to med errors, FDA warnsJune 7, 2021Much like how FDA monitors medication errors that affect people, the agency watches out for mistakes that may harm animals, too.
Antimicrobials see second-lowest year for salesDecember 11, 2019Antimicrobials for use in food-producing animals have maintained low volume of sales and distribution in recent years.
FDA approves ProHeart 12July 8, 2019The U.S. Food and Drug Administration’s (FDA’s) Center for Veterinary Medicine (CVM) has approved ProHeart 12 (moxidectin) extended release injectable suspension for dogs one year and older.
Aratana Therapeutics' Nocita 10 ml gets FDA approvalJune 13, 2019Aratana Therapeutics announced the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has approved an additional vial size (10 ml) of Nocita. "Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries," says Aratana Therapeutics chief development officer, Ernst Heinen, DVM, PhD. "Ultimately, we believe a smaller vial size may allow for expanded use and improve the level of care veterinarians provide for certain painful surgeries." Nocita, which is currently available in a 20-ml vial size, is a local postoperative analgesia for cranial cruciate ligament surgery in dogs and a peripheral nerve block following owner-elected onychectomy (declawing) in cats. The smaller vial size is expected to be made commercially available in fall 2019.
